Drug Trial Radar · NCT00548379
Kabul Vitamin D Supplementation Trial
Last checked: Nov 20, 2026Latest source record: May 16, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,048
Actual
Start
Nov 2007
Primary completion
Jun 2009
Study completion Jul 2009
Sponsor
- Lead sponsor
- London School of Hygiene and Tropical MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wellcome Trust; Aga Khan Health Services; Aga Khan University; Maywand Hospital, Kabul
- First posted
- Oct 24, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 1 month, up to 11 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Background: Pneumonia is the leading cause of childhood mortality, accounting for 19% of the 10.6 million deaths that occur each year1. Case-control studies from Ethiopia2 and India3 suggest that sub-clinical vitamin D deficiency may increase ten times the risk of pneumonia in children. We postulate that controlling childhood vitamin D deficiency has the potential to dramatically reduce the incidence of pneumonia and save \>700,000 lives each year since vitamin D deficiency is widespread in developing countries. Aim: To investigate whether 3-monthly oral supplementation of 100,000iu vitamin D reduces pneumonia and its consequences among children aged 1-12 months (followed for 18 months), living in a deprived area of Kabul, Afghanistan, where \>70% of young children are vitamin D deficient (\<8ng/dl). The effect of vitamin D on the incidence of other diseases, in particular diarrhea and rickets will also be investigated. Methods: Randomised double-blind placebo-controlled trial: 3000 children will be randomised to receive either 6 doses of vitamin D or placebo. The first dose will be given at the start of autumn and the second and subsequent doses every 3 months thereafter; children will be followed for 18 months. Incidence of pneumonia will be ascertained though weekly home visits (active surveillance) and from attendances and admissions at the trial clinic and wards in the hospital serving the study area (passive surveillance).
Conditions
- Pneumonia
- Vitamin D Deficiency
Interventions
vitamin DDrug
vitamin D 100,000 units once in 3 months
placeboDrug
olive oil 1ml
Primary outcomes
What the sponsor says the trial is designed to measure.
- incidence of pneumoniaTime frame: 18 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Maywand Hospital
Kabul, Afghanistan
Aga Khan Health Services
Kabul, Kabul, Afghanistan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.